News

Takeda Pharmaceutical Reports 15% Decline in First-Quarter Net Profit

1 Mins read

Takeda Pharmaceutical, the Japanese drugmaker, announced a 15% decrease in its first-quarter net profit compared to the previous year, despite experiencing revenue growth in various key business areas. The net profit for the quarter ended June 30 amounted to ¥89.395 billion ($637.4 million). It is important to note that the year-earlier period had seen a rise in the company’s bottom line due to financial gains associated with acquisitions.

The reported profit fell below the estimate of ¥113.53 billion as predicted by a poll of analysts conducted by S&P Global Market Intelligence.

On a positive note, Takeda’s first-quarter revenue saw a year-on-year increase of 8.9%, reaching ¥1.059 trillion. This growth can be attributed to a weaker yen and expansion in key business sectors, except for oncology. Notably, sales of the ulcerative colitis drug Entyvio surged by 14% from the previous year, amounting to ¥192.0 billion.

Moreover, Takeda’s operating profit margin demonstrated improvement, rising to 15.9% compared to 15.5% in the same period last year.

Despite these financial results, Takeda Pharmaceutical has decided to maintain its revenue and net-profit projections for the fiscal year ending in March 2024. The company expects a 4.7% decline in revenue, totaling ¥3.840 trillion, and anticipates a 55% decrease in net profit, amounting to ¥142.00 billion.

Related posts
News

What happens if $FUN hits $0.10? Price scenarios, holder behaviour, and post-breakout plans

3 Mins read
What if a simple $100 investment today could become $1,000 by Christmas? FUNToken sits at $0.009978 on June 30, 2025, just pennies…
News

AAS MINER Announces the Launch of an Innovative Free Cloud Mining Mobile App for Crypto Enthusiasts Worldwide, Opening a New Era of Digital Asset Mining

4 Mins read
LONDON, UK, July 04, 2025 (GLOBE NEWSWIRE) — AAS MINER Announces the Launch of an Innovative Free Cloud Mining Mobile App for…
News

Is Strategy Stock (MSTR) Still a Buy After a 210% Jump?

1 Mins read
Strategy (MSTR) stock has soared about 210% over the past year, fueled by its bold bet on Bitcoin (BTC). For many investors,…

Leave a Reply

Your email address will not be published. Required fields are marked *